CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts

Anticancer combination therapy has been developed to increase efficacy by enhancing synergy. Patient-derived xenografts (PDXs) have emerged as reliable preclinical models to develop effective treatments in translational cancer research. However, most PDX combination study designs focus on single dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Licai, Wang, Jing, Fang, Bingliang, Meric-Bernstam, Funda, Roth, Jack A., Ha, Min Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338066/
https://www.ncbi.nlm.nih.gov/pubmed/35906256
http://dx.doi.org/10.1038/s41598-022-16933-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338066/
https://www.ncbi.nlm.nih.gov/pubmed/35906256
http://dx.doi.org/10.1038/s41598-022-16933-6

Ejemplares similares